Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds
A method of treating non-small cell lung cancer in a mammal by administering to a patient a pharmaceutically acceptable amount of a compound being a thienotriazolodiazepine compound of the Formula (1) wherein R 1 is alkyl having a carbon number of 1-4, R 2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, R 3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —NR 5 —(CH 2 ) m —R 6 wherein R 5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and R 6 is phenyl or pyridyl optionally substituted by a halogen atom; or —NR 7 —CO—(CH 2 ) n —R 8 wherein R 7 is a hydrogen atom or alkyl having a carbon number of 1-4, n is an integer of 0-2, and R 8 is phenyl or pyridyl optionally substituted by a halogen atom, and R 4 is —(CH 2 ) a —CO—NH—R 9 wherein a is an integer of 1-4, and R 9 is alkyl having a carbon number of 1-4; hydroxyalkyl having a carbon number of 1-4; alkoxy having a carbon number of 1-4; or phenyl or pyridyl optionally substituted by alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4, amino or a hydroxyl group or —(CH 2 ) b —COOR 10 wherein b is an integer of 1-4, and R 10 is alkyl having a carbon number of 1-4, or a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof.
1. A method of treating non-small cell lung cancer in a mammal comprising the step of:
administering to a patient a pharmaceutically acceptable amount of a compound which is amorphous (S)-2[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide dihydrate formed as a solid dispersion comprising a pharmaceutically acceptable polymer which is hydroxypropylmethylcellulose acetate succinate wherein the compound to hydroxypropylmethylcellulose acetate succinate weight ratio of 1:3 to 1:1, wherein the solid dispersion exhibits an X-ray powder diffraction pattern substantially free of diffraction lines associated with crystalline (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f-][1,2,-4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide dehydrate and a single glass transition temperature (Tg) inflection point ranging from about 130° C. to about 140° C.
2. The method according to claim 1 , further comprising administering to the patient an mTOR inhibitor.
3. The method according to claim 2 , wherein the mTOR inhibitor is everolimus.
4. The method according to claim 1 , further comprising administering to the patient an ALK inhibitor.
5. The method according to claim 4 , wherein the ALK inhibitor is crizotinib.
6. The method according to claim 1 , wherein the non-small-cell lung cancer is EML4-ALK positive.
7. The method according to claim 1 , wherein the non-small-cell lung cancer exhibited down regulation of N-MYC mRNA levels after treatment.
8. The method according to claim 1 , wherein the non-small-cell lung cancer expressed BRD4/3/2, c-MYC, BCL-2, p21 and CyclinD1.
9. The method according to claim 1 , wherein the treatment induces a transient up-regulation of STAT3 with a subsequent down-regulation after 24 hour and up to 72 hour exposure.
10. The method according to claim 1 , wherein the non-small-cell lung cancer is EML4-ALk negative.
11. The method according to claim 10 , wherein the non-small-cell lung cancer expressed BRD4/3/2, c-MYC, BCL-2, p21 and CyclinD1.
12. The method according to claim 10 , wherein the treatment induces a transient up-regulation of STAT3 with a subsequent down-regulation after 24 hour and up to 72 hour exposure.
13. The method according to claim 1 , wherein the non-small-cell lung cancer has a mutation in the KRAS gene.
14. The method according to claim 1 , wherein the non-small-cell lung cancer has a mutation in the LKB1 gene.
15. The method according to claim 1 , wherein NMYC is downregulated.
16. The method according to claim 1 , wherein HEXIM is upregulated.